Cita APA

Luke, J. J., Ascierto, P. A., Khattak, M. A., Cruz Merino, L. d. l., Del Vecchio, M., Rutkowski, P., & Long, G. V. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study.

Citación estilo Chicago

Luke, Jason J., Paolo A. Ascierto, Muhammad A. Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, y Georgina V. Long. Pembrolizumab Versus Placebo As Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-free Survival in the Phase III KEYNOTE-716 Study. 2024.

Cita MLA

Luke, Jason J., et al. Pembrolizumab Versus Placebo As Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-free Survival in the Phase III KEYNOTE-716 Study. 2024.